FDA approves Gilead's Bixlenvo, a single-tablet option for HIV patients on complex regimens
New CapabilitiesThe pill pairs bictegravir with lenacapavir for virologically suppressed adults
Yesterday: FDA approves Gilead's BixlenvoNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated YesterdayRoughly 5% of Americans living with HIV take their antiretrovirals as several pills a day, because resistance, side effects, or other medications rule out standard single tablets. On Thursday the FDA approved a pill built for that group.
Gilead's Bixlenvo combines bictegravir, the backbone of its blockbuster Biktarvy, with lenacapavir, a newer capsid inhibitor with no cross-resistance to other antiretrovirals. The 30-day list price is $4,595, and Gilead says the tablet is the smallest once-daily single-tablet HIV regimen yet.
Why it matters
The 5% of US HIV patients stuck on daily multi-pill regimens finally have a single-tablet option.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
The dominant maker of HIV single-tablet regimens, now adding a bictegravir-lenacapavir pill to its portfolio.
The US regulator that cleared Bixlenvo for virologically suppressed adults with HIV.
Timeline
March 2026 August 2026
-
FDA approves Gilead's Bixlenvo
Latest RegulatoryAgency clears the once-daily bictegravir/lenacapavir tablet, the first single-tablet regimen for HIV patients on complex multi-pill regimens.
-
ARTISTRY-1 results published in The Lancet
ResearchPhase 3 data show bictegravir plus lenacapavir maintains viral suppression at 48 weeks in virologically suppressed adults.
Historical Context
2 moments from history that rhyme with this story — and how they unfolded.
Atripla, the first once-daily HIV pill (2006)
The FDA approved Atripla, the first single-tablet HIV regimen, combining efavirenz, emtricitabine, and tenofovir. It collapsed what had been multi-pill 'cocktail' therapy into one daily tablet.
Within a few years, once-daily single tablets became the default for most newly treated patients.
The single-tablet era shifted HIV care from pill burden toward simplicity, setting the template Bixlenvo follows.
Bixlenvo is the latest chapter in the same consolidation: shrinking complex regimens into one pill, this time for patients with drug resistance.
Biktarvy launch (2018)
Gilead launched Biktarvy, a three-drug single tablet built on bictegravir. It became the most-prescribed HIV treatment in the US within a few years.
Biktarvy set the standard for high-barrier, low-toxicity single tablets.
Its success made bictegravir the workhorse backbone of Gilead's HIV franchise, which Bixlenvo now pairs with lenacapavir.
Bixlenvo keeps bictegravir's proven profile but adds lenacapavir, targeting patients Biktarvy cannot serve.
